DNA vaccines against leptospirosis: A literature review. (Q40062129)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

title

DNA vaccines against leptospirosis: A literature review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

Marcelle Moura Silveira

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Thaís Larré Oliveira

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Rodrigo Andrade Schuch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Daiane Drawanz Hartwig

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

language of work or name

English

0 references

publication date

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

5559-5567

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

Mannosylated LigANI produced in Pichia pastoris protects hamsters against leptospirosis.

29 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Leptospirosis in Mexico: Epidemiology and Potential Distribution of Human Cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

A prime-boost strategy using the novel vaccine candidate, LemA, protects hamsters against leptospirosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Global Burden of Leptospirosis: Estimated in Terms of Disability Adjusted Life Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Prevalence and risk factors for Leptospira exposure in New Zealand veterinarians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

The use of halloysite clay and carboxyl-functionalised multi-walled carbon nanotubes for recombinant LipL32 antigen delivery enhanced the IgG response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Diagnosis of Leptospirosis: Comparison between Microscopic Agglutination Test, IgM-ELISA and IgM Rapid Immunochromatography Test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Current status of leptospirosis in Japan and Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Safety and immunogenicity of subcutaneous or intramuscular administration of a monovalent inactivated vaccine against Leptospira interrogans serogroup Icterohaemorrhagiae in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Improving the safety of viral DNA vaccines: development of vectors containing both 5' and 3' homologous regulatory sequences from non-viral origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Enhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Strategies and hurdles using DNA vaccines to fish.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

DNA vaccines: a simple DNA sensing matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Synthetic DNA vaccine strategies against persistent viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Differential TLR recognition of leptospiral lipid A and lipopolysaccharide in murine and human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Immune evasion by pathogenic Leptospira strains: the secretion of proteases that directly cleave complement proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Leptospirosis: aspects of innate immunity, immunopathogenesis and immune evasion from the complement system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Characteristic features of intracellular pathogenic Leptospira in infected murine macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Rapid translocation of polarized MDCK cell monolayers by Leptospira interrogans, an invasive but nonintracellular pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Recombinant LipL32 and LigA from Leptospira are unable to stimulate protective immunity against leptospirosis in the hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Evaluation of 238 antigens of Leptospira borgpetersenii serovar Hardjo for protection against kidney colonisation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Evaluation of the Leptospira interrogans Outer Membrane Protein OmpL37 as a Vaccine Candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Evaluation of type 1 immune response in naïve and vaccinated animals following challenge with Leptospira borgpetersenii serovar Hardjo: involvement of WC1(+) gammadelta and CD4 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

A Leptospira borgpetersenii Serovar Hardjo Vaccine Induces a Th1 Response, Activates NK Cells, and Reduces Renal Colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

TLR4- and TLR2-mediated B cell responses control the clearance of the bacterial pathogen, Leptospira interrogans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Cross-Reactivity of Antibodies against Leptospiral Recurrent Uveitis-Associated Proteins A and B (LruA and LruB) with Eye Proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against leptospira.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

DNA vaccines: ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

An improved plasmid DNA expression vector for direct injection into skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

LipL41, a hemin binding protein from Leptospira santarosai serovar Shermani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Recombinant vaccines against leptospirosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Production and characterization of a polyclonal antibody of anti-rLipL21-IgG against leptospira for early detection of acute leptospirosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Leptospiral outer membrane protein LipL41 is not essential for acute leptospirosis but requires a small chaperone protein, lep, for stable expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

LipL32 Is a Subsurface Lipoprotein of Leptospira interrogans: presentation of new data and reevaluation of previous studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Leptospiral extracellular matrix adhesins as mediators of pathogen-host interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Protection against lethal leptospirosis after vaccination with LipL32 coupled or coadministered with the B subunit of Escherichia coli heat-labile enterotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Evaluation of cell binding activities of Leptospira ECM adhesins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

A conserved region of leptospiral immunoglobulin-like A and B proteins as a DNA vaccine elicits a prophylactic immune response against leptospirosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fibrinogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

OmpL1 is an extracellular matrix- and plasminogen-interacting protein of Leptospira spp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Surfaceome of Leptospira spp.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

LipL21 Is a Novel Surface-Exposed Lipoprotein of Pathogenic Leptospira Species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Identification of immunodominant B- and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of Leptospira interrogans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Protection of guinea pigs against Leptospira interrogans serovar Lai by LipL21 DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

The OmpA-like protein Loa22 is essential for leptospiral virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Leptospira as an Emerging Pathogen: A Review of its Biology, Pathogenesis and Host Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Characterization of the outer membrane proteome of Leptospira interrogans expressed during acute lethal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Immunogenicity of a DNA and Recombinant Protein Vaccine Combining LipL32 and Loa22 for Leptospirosis Using Chitosan as a Delivery System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Novel 45-kilodalton leptospiral protein that is processed to a 31-kilodalton growth-phase-regulated peripheral membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Comparative subproteome analysis of three representative Leptospira interrogans vaccine strains reveals cross-reactive antigens and novel virulence determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Differential in vivo gene expression of major Leptospira proteins in resistant or susceptible animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Technologies for enhanced efficacy of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Mechanisms of action of adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Chitosan functionalisation of gold nanoparticles encourages particle uptake and induces cytotoxicity and pro-inflammatory conditions in phagocytic cells, as well as enhancing particle interactions with serum components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

The inflammasome: an integrated view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Adjuvants in veterinary vaccines: modes of action and adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Key roles of adjuvants in modern vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Aβ antibodies induced by multimeric protein antigen (1-11)E2, preserving the Igg1-skewed isotype distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Recombinant vaccines and the development of new vaccine strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

DNA vaccination of poultry: The current status in 2015.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.067

10.1016/J.VACCINE.2017.08.067

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28882437%20AND%20SRC:MED&resulttype=core&format=json